- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03770325
A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine
Effect of Berberine on Cardiovascular Disease Risk Factors: a Mechanistic Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives: to assess the effect of berberine on a set of well-established CVD risk factors, including lipids, systolic and diastolic blood pressure, coagulation factors, fasting glucose, insulin, adiposity (body mass index (BMI) and waist-hip ratio (WHR)) and the mediation via testosterone and/or sex hormone binding globulin using a mechanistic, parallel RCT.
Study design: a mechanistic, randomized, double-blind, placebo-controlled, parallel trial in 84 Chinese men in Hong Kong.
Interventions: the eligible participants will be randomized to take berberine (500 mg orally twice a day) or placebo for 12 weeks. Blood samples will be taken at baseline, 8-week and 12-week intervention.
Data analysis and expected results: the investigators will use an intention to treat analysis, with multiple imputation for missing data. The investigators will compare the baseline characteristics of participants in the two arms using analysis of variance. The investigators will assess the effects of berberine on changes in CVD risk factors using analysis of variance, and the mediation using causal mediation analysis. Compared to the placebo group, the participants receiving berberine are expected to have lower burden of cardiovascular disease risk factors at the end of the intervention. These effects may be mediated or partly mediated by lowering testosterone.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Li Ka Shing Faculty of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Men, who are
- aged 20 to 65 years
- of Chinese ethnicity
- with hyperlipidemia, defined as TG greater than 150 mg/dl (1.70 mmol/L), TC greater than 200 mg/dl (5.16 mmol/L), and/or LDL-c greater than 100 mg/dl (2.58 mmol/L)
- willing to make return visits
- not currently receiving hormone replacement therapy, such as testosterone replacement therapy, in the past 12 months
- not currently taking berberine or traditional Chinese medicine that contains berberine, in the past 1 month
- free of any congenital diseases, including familial hypercholesterolemia
- free of any infectious diseases, e.g. seasonal influenza
- free of anemia and glucose-6-phosphate dehydrogenase deficiency
- with no history of any chronic diseases including ischemic heart disease, myocardial infarction (heart attack), stroke, diabetes, cancer, liver/renal dysfunction, and gastrointestinal disorders.
Exclusion Criteria:
- All women, and men, who did not meet the aforementioned inclusion criteria, and/or unable or unwilling to provide consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Berberine
berberine (500 mg orally twice a day)
|
Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
|
Placebo Comparator: Placebo
placebo (500 mg orally twice a day)
|
Placebo tablets, prepared with the same appearance, for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
lipid profile
Time Frame: change from baseline lipid profile at 8 weeks
|
LDL-cholesterol, HDL-cholesterol, triglycerides and total cholesterol in mmol/L
|
change from baseline lipid profile at 8 weeks
|
lipid profile
Time Frame: change from baseline lipid profile at 12 weeks
|
LDL-cholesterol, HDL-cholesterol, triglycerides and total cholesterol in mmol/L
|
change from baseline lipid profile at 12 weeks
|
blood pressure
Time Frame: change from baseline blood pressure at 8 weeks
|
systolic blood pressure and diastolic blood pressure in mmHg
|
change from baseline blood pressure at 8 weeks
|
blood pressure
Time Frame: change from baseline blood pressure at 12 weeks
|
systolic blood pressure and diastolic blood pressure in mmHg
|
change from baseline blood pressure at 12 weeks
|
thromboxane A2
Time Frame: change from baseline thromboxane A2 at 8 weeks
|
thromboxane A2 in mmol/L
|
change from baseline thromboxane A2 at 8 weeks
|
thromboxane A2
Time Frame: change from baseline thromboxane A2 at 12 weeks
|
thromboxane A2 in mmol/L
|
change from baseline thromboxane A2 at 12 weeks
|
testosterone
Time Frame: change from baseline testosterone at 8 weeks
|
testosterone in mmol/L
|
change from baseline testosterone at 8 weeks
|
testosterone
Time Frame: change from baseline testosterone at 12 weeks
|
testosterone in mmol/L
|
change from baseline testosterone at 12 weeks
|
body mass index (BMI)
Time Frame: change from baseline body mass index at 8 weeks
|
weight and height will be combined to report BMI in kg/m^2
|
change from baseline body mass index at 8 weeks
|
body mass index (BMI)
Time Frame: change from baseline body mass index at 12 weeks
|
weight and height will be combined to report BMI in kg/m^2
|
change from baseline body mass index at 12 weeks
|
waist hip ratio
Time Frame: change from baseline waist hip ratio at 8 weeks
|
waist circumstance and hip circumstance will be combined to report waist hip ratio
|
change from baseline waist hip ratio at 8 weeks
|
waist hip ratio
Time Frame: change from baseline waist hip ratio at 12 weeks
|
waist circumstance and hip circumstance will be combined to report waist hip ratio
|
change from baseline waist hip ratio at 12 weeks
|
fasting glucose
Time Frame: change from baseline fasting glucose at 8 weeks
|
fasting glucose in mmol/L
|
change from baseline fasting glucose at 8 weeks
|
fasting glucose
Time Frame: change from baseline fasting glucose at 12 weeks
|
fasting glucose in mmol/L
|
change from baseline fasting glucose at 12 weeks
|
fasting insulin
Time Frame: change from baseline fasting insulin at 8 weeks
|
fasting insulin in mmol/L
|
change from baseline fasting insulin at 8 weeks
|
fasting insulin
Time Frame: change from baseline fasting insulin at 12 weeks
|
fasting insulin in mmol/L
|
change from baseline fasting insulin at 12 weeks
|
liver function
Time Frame: change from baseline fasting insulin at 8 weeks
|
Alanine transaminase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), total bilirubin, Gamma-glutamyltransferase, total protein and albumin in mmol/L
|
change from baseline fasting insulin at 8 weeks
|
liver function
Time Frame: change from baseline fasting insulin at 12 weeks
|
Alanine transaminase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), total bilirubin, Gamma-glutamyltransferase, total protein and albumin in mmol/L
|
change from baseline fasting insulin at 12 weeks
|
sex hormone binding globulin (SHBG)
Time Frame: change from baseline SHBG at 8 weeks
|
SHBG in nmol/L
|
change from baseline SHBG at 8 weeks
|
sex hormone binding globulin (SHBG)
Time Frame: change from baseline SHBG at 12 weeks
|
SHBG in nmol/L
|
change from baseline SHBG at 12 weeks
|
thrombin time
Time Frame: change from baseline thrombin time at 8 weeks
|
thrombin time in sec
|
change from baseline thrombin time at 8 weeks
|
thrombin time
Time Frame: change from baseline thrombin time at 12 weeks
|
thrombin time in sec
|
change from baseline thrombin time at 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jie Zhao, PhD, The University of Hong Kong
Publications and helpful links
General Publications
- Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81. doi: 10.1016/j.jep.2014.09.049. Epub 2014 Dec 10.
- Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008 Aug;22(8):999-1012. doi: 10.1002/ptr.2399.
- Skarydova L, Hofman J, Chlebek J, Havrankova J, Kosanova K, Skarka A, Hostalkova A, Plucha T, Cahlikova L, Wsol V. Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem Mol Biol. 2014 Sep;143:250-8. doi: 10.1016/j.jsbmb.2014.04.005. Epub 2014 Apr 24.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 15162621
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University Hospital, BrestRecruiting
-
University Hospitals Cleveland Medical CenterRecruitingCardiovascular Risk FactorUnited States
-
Northwestern UniversityNorthShore University HealthSystem; Case Western Reserve University; Shirley... and other collaboratorsCompleted
-
University of ArizonaTerminatedCardiovascular Risk FactorUnited States
-
Penn State UniversityCompletedCardiovascular Risk FactorUnited States
-
Clinique BizetCompleted
-
University Hospital, BrestCompleted
-
University of DelawareCompleted
Clinical Trials on Berberine
-
Tianjin Anding HospitalCompletedSchizophrenia | Metabolic Syndrome | FemaleChina
-
University of FloridaFlorida High Tech Corridor Council; Designs for Health, Inc.Completed
-
EuroPharma, Inc.Scientific Center of Drug and Medical Technologies Expertise of the Ministry... and other collaboratorsNot yet recruiting
-
Xijing Hospital of Digestive DiseasesCompleted
-
Factors Group of Nutritional Companies Inc.CompletedPharmacokineticsCanada
-
National Cancer Institute (NCI)CompletedUlcerative ColitisUnited States, China
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Tang YidaChinese Society of CardiologyNot yet recruitingMetabolic SyndromeChina
-
Ayub Teaching HospitalCompletedPolycystic Ovary SyndromePakistan
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedDiabetes Mellitus | Chronic Kidney DiseaseChina